北京热景生物技术股份有限公司关于以集中竞价交易方式回购股份的回购报告书

Core Viewpoint - The company plans to repurchase shares through a centralized bidding method, with a total repurchase amount between RMB 100 million and RMB 200 million, aimed at employee stock ownership plans or equity incentives [2][31]. Group 1: Repurchase Plan Details - Total repurchase amount: Not less than RMB 100 million and not more than RMB 200 million [2][31]. - Source of funds: Self-owned funds [3][17]. - Purpose of repurchase: To be used for employee stock ownership plans or equity incentives [3][10]. - Price cap for repurchase: Not exceeding RMB 244.00 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [3][16]. - Method of repurchase: Centralized bidding trading method [4][11]. - Duration of repurchase: Within 12 months from the board's approval date [5][12]. Group 2: Implementation and Compliance - The board approved the repurchase plan on November 11, 2025, with unanimous support from all directors present [7][9]. - The repurchase plan does not require shareholder meeting approval as per relevant regulations [8][9]. - The company has established a dedicated securities account for the repurchase [28]. Group 3: Progress of Repurchase - As of November 12, 2025, the company has repurchased 202,540 shares, representing 0.2185% of the total share capital, with a total expenditure of approximately RMB 30 million [33]. - The lowest purchase price was RMB 145.59 per share, and the highest was RMB 152.18 per share [33]. Group 4: Future Plans and Governance - The company will continue to monitor market conditions and make repurchase decisions accordingly, ensuring compliance with relevant regulations [28][33]. - There are currently no clear plans for share reduction by major shareholders or executives in the next three to six months [5][21].